Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

AdamaxvsCortagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited
BAnimal-MechanisticHUMAN-REVIEWED11/35 cited
Adamax
ACTH(4-10) Analogue · Russian Nootropic
1.4×BDNF protein ↑Dolotov 2006
BDNF mRNA (exon III)Dolotov 2006
1.6×trkB phosphorylationDolotov 2006
Intranasal · Research Use Only
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
TetrapeptideStructure
↓ LPO productsAntioxidant effectKozina 2007
AnimalEvidence level
Injectable · Animal models

01Mechanism of Action

Parameter
Adamax
Cortagen
Primary target
Melanocortin receptors (MC-Rs) in hippocampus and cortex
Cerebral cortex tissue — molecular targets under investigation
Pathway
ACTH(4-10) fragment → MC-R binding → BDNF/trkB upregulation → neurotrophic signaling
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Downstream effect
Increased hippocampal BDNF expression, trkB tyrosine phosphorylation, enhanced conditioned avoidance learning, circadian rhythm normalizationDolotov 2006Arushanian 2008
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Feedback intact?
Non-endocrine — devoid of adrenal axis effectsvan 1978
Origin
ACTH(4-10) fragment with modified amino acid sequence at positions 8, 9, 10Teter 2001
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Antibody development

02Dosage Protocols

Parameter
Adamax
Cortagen
Animal dose (rat)
50 mcg/kg body weightDolotov 2006
Single intranasal application; produced maximal BDNF response.
Route
Injectable (inferred from animal protocols)
Frequency
Single-dose or chronic administration protocols
Chronic dosing normalized circadian rhythms; single-dose produced acute BDNF elevation.
Human dose (exploratory)
Not established — limited human data
ACTH(4-10) and analogs dosed 30–60 mcg intranasally in early human studies.
Evidence basis
Animal (rodent, rabbit) studies; minimal human RCT data
Animal mechanistic studies
Timing
Variable — chronic administration for circadian effects
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.

04Side Effects & Safety

Parameter
Adamax
Cortagen
Cardiovascular effects
ACTH(4-10) fragments may have pressor and cardioaccelerator actions at high dosesGruber 1984
Effects attenuated by α/β-receptor antagonists; observed at 30–1000 nmol/kg IV in rats.
Natriuretic effect
ACTH(4-10) exhibited natriuretic activity at lower doses (7 nmol/kg)Gruber 1984
Behavioral suppression
Suppression of aggression, reduced orientation-cognition reactions in rabbitsTeter 2001
May reflect anxiolytic or stress-dampening profile.
Long-term safety
Unknown — chronic human safety data lacking
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
Absolute Contraindications
Adamax
  • ·Pregnancy and lactation (precautionary; no data)
  • ·Active cardiovascular instability (due to potential pressor effects)
Cortagen
Relative Contraindications
Adamax
  • ·Hypertension (monitor BP if using higher doses)
  • ·Renal impairment (natriuretic effects may alter electrolyte balance)
Cortagen

05Administration Protocol

Parameter
Adamax
Cortagen
1. Reconstitution (if lyophilised)
Add sterile water or bacteriostatic water to lyophilised vial per manufacturer guidance. Roll gently — do not shake. Ensure clarity before use.
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
2. Route
Intranasal administration is the primary route in animal and exploratory human studies. Delivered via nasal spray or dropper to ensure mucosal absorption.Dolotov 2006Smolnik 2000
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
3. Timing
Variable. Single-dose protocols for acute cognitive tasks; chronic daily dosing for circadian rhythm normalization and sustained neuroprotection.
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
4. Storage
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within manufacturer-specified timeframe.
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

06Stack Synergy

Adamax
+ Semax
Moderate
View Semax

Both Adamax and Semax are ACTH(4-10)-derived nootropics acting via melanocortin receptors and BDNF upregulation. Adamax has distinct amino acid modifications at positions 8-10, potentially offering complementary receptor binding profiles or metabolic stability. Stacking may amplify neurotrophic signaling and cognitive enhancement, though direct synergy studies are absent. Theoretical multi-pathway benefit.

Adamax
Research dose intranasal
Semax
300–600 mcg intranasal
Frequency
Once daily, morning or pre-cognitive task
Primary benefit
Enhanced BDNF upregulation, cognitive performance, neuroprotection
Cortagen
— no documented stacks